#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Splenic marginal zone lymphoma Arrhythmia Hereditary neuropathic amyloidosis Thermal burn Noonan syndrome Pseudomyxoma peritonei Non-small cell lung cancer metastatic Oesophageal carcinoma Nodal marginal zone B-cell lymphoma CDKL5 deficiency disorder Angiosarcoma Oropharyngeal cancer recurrent Gastrointestinal stromal tumour Plasma cell myeloma refractory Cytokine release syndrome More trials…

    Learn about Rare Diseases

    Systemic sclerosis pulmonary – Trials in Disease Retinoblastoma – Life with Disease Ewing’s sarcoma recurrent – Diagnostics Usher’s syndrome – Life with Disease Usher’s syndrome – Basic Information Encephalitis autoimmune – Trials in Disease Paroxysmal nocturnal haemoglobinuria – Basic Information Breast angiosarcoma metastatic – Treatment Mantle cell lymphoma refractory – Basic Information Chondrosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ipn01194 Pehero ZOREVUNERSEN SODIUM Pbf-999 Cenegermin Oritavancin Argatroban Monohydrate Eribulin Cetirizine Dihydrochloride Dydrogesterone Exl01 Betula Alba Pollen Extract Glycopyrronium Bromide Meglumine Gadoterate Gefurulimab Etidronate Disodium Xxb750 FLUCLOXACILLIN SODIUM BIIB115 Epirubicin More therapies…

    Learn about Your Condition

    Carpal tunnel syndrome Large cell lung cancer Bone hypertrophy Amyloidosis Exfoliation glaucoma Food allergy Gastric cancer Cough Eructation Diabetic nephropathy Pemphigoid Cerebral amyloid angiopathy Anal incontinence Osteoarthritis Agitation postoperative More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Myelofibrosis

  • Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Navtemadlin
    • Ruxolitinib
    France Italy

  • Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Navtemadlin
    • Danazol
    • Hydroxycarbamide
    Bulgaria Croatia Czechia France Germany Greece +7

  • Study on Luspatercept for Treating Anemia in Adults with Myelofibrosis on JAK2 Inhibitor Therapy Requiring Red Blood Cell Transfusions

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Luspatercept
    • Sodium Chloride
    Austria Belgium Czechia France Germany Greece +6

  • Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • ALKYLATING AGENTS
    • ANTIMETABOLITES
    • Imetelstat Sodium
    Austria Belgium Bulgaria Denmark France Germany +5

  • Study Comparing Fedratinib with Drug Combination for Myelofibrosis in Patients Previously Treated with Ruxolitinib

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • Busulfan
    • Danazol
    • Dimethyl Fumarate
    Austria Belgium Czechia France Germany Hungary +4

  • Study on the Safety and Effects of Navitoclax and Ruxolitinib for Patients with Myelofibrosis and Myeloproliferative Neoplasms

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Myeloproliferative neoplasm
    • Myelofibrosis
    Investigated Drugs:
    • Navitoclax
    • Celecoxib
    • Ruxolitinib
    Bulgaria Croatia France Germany Italy Spain
Previous Page
1 2 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!